Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Helpt u mee?
Helpt u mee?
  • Home
  • Lindy Vernooij

Lindy Vernooij

PhD Student
Lindy is PhD student binnen de Molenaar groep.
Phone
Email L.Vernooij-4@prinsesmaximacentrum.nl

Publicaties

6 publicaties in totaal

  • Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine

    • mrt. 2025
    • Karin P.S., Langenberg, et al
    • European Journal of Cancer

  • Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma

    • jun. 2024
    • Lindy, Vernooij, et al
    • EJC Paediatric Oncology

  • MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

    • jan. 2023
    • Thomas F., Eleveld, et al
    • Frontiers in Oncology

  • MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

    • jan. 2023
    • Thomas F, Eleveld, et al
    • Frontiers in Oncology

  • High-throughput screening identifies idasanutlin as a resensitizing drug for venetoclax-resistant neuroblastoma cells

    • jun. 2021
    • Lindy, Vernooij, et al
    • Molecular Cancer Therapeutics
Bekijk alle publicaties